CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on genomics, today announced that it is scheduled to present at LD MICRO’s 5th Annual Conference on Thursday, December 6, 2013, at 10 a.m. Pacific Standard Time. The December 5-6 conference is to be held at the Luxe Sunset Bel Air Hotel at 11461 Sunset Boulevard in Los Angeles, CA.
CollabRx Chairman and Co-CEO Thomas R. Mika will be presenting to investors and available for one-on-one meetings during the conference.
CollabRx uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on molecular medicine with specific insights from the nation’s top clinical experts. The company combines proprietary content and technology to provide clinically relevant and dynamically updated knowledge on clinical trials, drugs, biologics and other information relevant for cancer treatment planning. This knowledge is supported by CollabRx’s large and growing network of over 50 leading clinical practitioners in the United States. While CollabRx and its advisors do not provide specific treatment recommendations, this clinically relevant knowledge is a key part of the “context engine” for informing healthcare decision-making.
About LD MICRO
LD MICRO is a by-invitation-only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The firm also hosts the LD MICRO Micro-Cap Growth Conference for institutional investors in December of each year. LD MICRO concentrates on finding, researching and investing in companies that are overlooked by most institutional investors. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.